Diatos S.A.

Diatos is a biopharmaceutical company headquartered in Paris, France with subsidiaries in Leuven, Belgium and the San Francisco Bay Area, USA.

Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution.

Diatos has built its portfolio of drugs and drug candidates through a selective strategy of license acquisitions as well as internal R&D activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug®. To date the company has advanced these compounds through 8 completed or ongoing clinical programs.

Diatos' portfolio includes DaunoXome®, a drug marketed for the treatment of Kaposi’s sarcoma and under review for the treatment of AML and two drugs in clinical development for the treatment of various solid tumours, DTS-301 and DTS-201. The portfolio of Diatos also includes drug candidates in the earlier stages of development.